Colorado Cannabis Vape Recall: Affected Products, Health Risks and What to Do

Executive summary

A Colorado cannabis vape recall expanded in October 2026 as health complaints rose, according to MJBizDaily, and the episode tests the state's product-safety system more than any event since the 2019 national vaping-lung-injury outbreak. MJBizDaily reported the expansion on October 15, 2026. This page is the standing reference for the recall: the regulatory machinery behind it, the history that explains it, and what it means for operators, investors, and patients.

Colorado regulates vapes under the Colorado Retail Marijuana Code and Medical Marijuana Code, both in Title 44, Article 10 of the Colorado Revised Statutes. The Marijuana Enforcement Division (MED) of the Colorado Department of Revenue licenses the industry and orders recalls. The Colorado Department of Public Health and Environment (CDPHE) handles the health-surveillance side. Because the plant remains a Schedule I substance under 21 U.S.C. § 812, the FDA has no jurisdiction over state-licensed vape cartridges. Recalls therefore depend on state regulators, licensee cooperation, and retailer follow-through.

The headline does not give a full product list, a case count, or a confirmed cause in the material available to us. We do not fill those gaps with guesses. Dated update sections will add confirmed facts as MED, CDPHE, and licensees publish them.

Three points matter most for readers:

• A recall expansion means more lots, brands, or batches were swept in after the initial action, which usually signals a shared upstream input such as oil, an additive, or hardware.
• Rising complaints are the leading indicator regulators watch, and they typically arrive before laboratory confirmation of a root cause.
• Consumers holding affected products should stop using them and return them to the point of sale until MED or the licensee confirms they are safe.

Why this matters

Vape cartridges are among the highest-volume, highest-margin concentrate formats in legal cannabis, so a contamination or quality failure reaches patients, retailers, and balance sheets at once. Colorado opened the first state-regulated adult-use market in 2014, and its enforcement choices tend to be copied or at least watched by other regulators.

Patients and consumers

Vapes are inhaled, so any contaminant, solvent residue, adulterant, or heavy metal from hardware goes straight to the lungs. Medical patients who rely on discreet, dose-controlled cartridges are among the most exposed. Colorado's medical program has been open since the 2000 passage of Amendment 20, and many of its patients use vapes for symptom management.

Operators

A recall hits a licensee in several places at once: pulled inventory, destroyed product, refunds, lost shelf space, and potential administrative action. Retailers must quarantine affected lots quickly. Brands must trace batches to the last unit. Cultivators and extractors who supplied the oil may face scrutiny even when the failure occurred downstream.

Investors and MSOs

Multi-state operators (MSOs) sell branded vapes across several markets. A Colorado recall raises questions about whether the same input, such as a distillate lot or a hardware supplier, flows into other states. Because 280E already limits deductions for cannabis businesses, inventory write-offs and recall costs fall on companies with thin after-tax margins. Colorado wholesale conditions have been competitive for several years, so there is little pricing cushion to absorb shocks.

Regulators and policymakers

A recall that expands over time pushes lawmakers to ask whether testing rules, ingredient restrictions, and hardware standards are adequate. It also feeds the federal debate: advocates for moving marijuana out of Schedule I cite product safety as a reason for federal standards, while opponents cite recalls as proof of regulatory weakness.

Background and history

Colorado's vape-safety regime grew in layers over twenty-five years, from a 2000 medical constitutional amendment to the testing and potency rules adopted after repeated contamination scares. Each layer was a reaction to a specific failure, and the present recall sits within that pattern.

2000: Amendment 20 creates medical cannabis

Colorado voters approved Amendment 20 in November 2000, adding a medical marijuana right to the state constitution. For roughly a decade the medical market operated with little formal product testing or licensing oversight. The first comprehensive regulatory structure came with the 2010 Medical Marijuana Code, which created a licensing system and an enforcement division.

2012–2014: Amendment 64 and the first retail market

Colorado voters passed Amendment 64 on November 6, 2012, legalizing adult-use cannabis for adults 21 and over. Licensed retail sales began on January 1, 2014, making Colorado the first U.S. state with a regulated adult-use market. The Retail Marijuana Code set up the MED as the single state licensing and enforcement body, with rulemaking authority over labeling, packaging, testing, and recalls.

2014–2016: Testing begins and pesticide scandals

Mandatory potency testing arrived with the first retail rules. Contaminant testing came later and unevenly. In 2015 and 2016, Denver health officials and MED dealt with products tied to unapproved pesticide use, including quarantines of plants and recalls of products. Those cases established the template that persists today: a regulator identifies a problem, licensees must trace affected lots, and products are held or destroyed.

The pesticide period also exposed a structural gap. Colorado had no list of approved pesticides built on inhalation toxicity, because no federal agency had evaluated pesticides for cannabis use. The state moved toward a broader pesticide testing regime in the following years.

2017–2018: Concentrate growth and extraction rules

Concentrates and vape cartridges grew quickly as a share of Colorado sales. Regulators focused on residual solvents from butane and other extraction methods, plus mandatory testing categories for each product class. Packaging and child-resistance rules also tightened as vapes entered mainstream retail.

2019–2020: EVALI and the national turning point

The most important event for understanding vape recalls is the 2019 outbreak of e-cigarette or vaping product use-associated lung injury (EVALI). The CDC reported that, as of February 18, 2020, 2,807 hospitalized EVALI cases and 68 deaths had been reported nationally. On November 8, 2019, the CDC announced that vitamin E acetate had been found in fluid from the lungs of all 29 patients tested, and it identified the additive as a strong culprit, with most cases linked to THC-containing products from informal sources.

The outbreak changed state policy. Massachusetts imposed a temporary statewide vape sales ban in September 2019 that lasted until December 2019. Many state regulators, Colorado's among them, issued guidance on additives and diluents. The lesson was that the legal market was safer than the illicit one, but not immune from additive and hardware risks.

2021–2023: Potency, concentrates, and legislative scrutiny

Colorado lawmakers passed HB 21-1317, a bill regulating high-potency concentrates, adding purchase limits and requiring more study of potency and health effects. The legislation reflected a shift in focus from adulterants to the intrinsic risks of very high-THC products. Concentrate regulation became a recurring topic in the General Assembly.

2024–2026: Federal flux and market stress

Federal policy moved on several fronts. The DEA's proposed rescheduling of marijuana to Schedule III went through the rulemaking process, including an NPRM and an administrative hearing track before an ALJ, and later executive-branch action sought to accelerate it. Separately, Congress changed the federal hemp definition in late 2025, with the new restrictions on intoxicating hemp products scheduled to take effect about a year after enactment, in November 2026. Check current federal status before relying on this summary, because both tracks have moved quickly.

In October 2026 the recall that anchors this page expanded. MJBizDaily's reporting tied the expansion to rising health complaints.

Timeline at a glance

Date	Event	Relevance to recalls
Nov 2000	Amendment 20 passes	Creates medical cannabis right; minimal initial testing
2010	Medical Marijuana Code enacted	First licensing and enforcement structure
Nov 6, 2012	Amendment 64 passes	Mandates adult-use regulation
Jan 1, 2014	Retail sales begin	MED gains retail rulemaking and recall authority
2015–2016	Pesticide quarantines and recalls	Sets the trace-and-hold template
2019	EVALI outbreak	Additive scrutiny; national vape policy shift
Feb 18, 2020	CDC final tally: 2,807 hospitalizations, 68 deaths	Benchmark for vape health-risk debates
2021	HB 21-1317 on concentrates	Potency and purchase-limit framework
Oct 15, 2026	MJBizDaily reports recall expansion	Complaints rising; scope widening

Key players

The recall involves a small set of actors with distinct powers: the MED orders and polices recalls, CDPHE tracks health effects, licensees execute the pull, and federal agencies mostly watch.

Colorado Marijuana Enforcement Division (MED)

The MED sits in the Colorado Department of Revenue and has authority over licensing, inspection, product testing rules, and enforcement under Title 44, Article 10. It can order licensees to stop selling a product, require trace-back, and impose administrative penalties. Its public health and safety notices are the first place operators should look for official recall scope.

Colorado Department of Public Health and Environment (CDPHE)

CDPHE monitors illness reports and coordinates with hospitals, poison centers, and local health departments. Complaint volume is a core signal. When it rises, CDPHE epidemiologists look for common exposures such as product type, brand, purchase date, and device.

Rocky Mountain Poison and Drug Safety

The state's poison control center collects exposure calls and adverse-event reports. Its data helps regulators distinguish a localized batch problem from a broader trend.

Licensed manufacturers, brands, and retailers

Product manufacturers and the retailers that sold their products carry the practical recall burden. This includes both Colorado-based independents and MSOs operating dispensaries in the state. Retailers must pull and quarantine affected lots, notify customers where practical, and document disposition. Operators depend heavily on their seed-to-sale tracking system, METRC, to identify every unit from a batch.

Federal agencies: FDA, CDC, and DEA

The FDA does not oversee state-licensed marijuana vapes, though it regulates hemp-derived and nicotine vapes under different authorities. The CDC provides national surveillance and case definitions, as with EVALI. The DEA controls scheduling, which determines whether federal product-safety standards can ever apply.

Advocates and opponents

Industry groups generally argue that regulated markets are safer than the illicit market and that prompt recalls show the system works. Public health advocates and some prevention groups cite recalls as evidence that testing and hardware standards need strengthening, and they push for tighter limits on high-potency concentrates.

Legal and regulatory framework

Colorado recalls rest on state statute and MED rules, because federal law treats marijuana as a Schedule I drug under 21 U.S.C. § 812 and leaves product safety to the states.